Sayfa yüklenirken bir hata oluştu.
Teknik ekibimiz bilgilendirildi, ancak sorunun devam etmesi durumunda lütfen e-posta destek widget ile bize ulaşın.
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM EBIT Multiple | 11,0x - 12,1x | 11,6x |
| Selected Fwd EBIT Multiple | 7,1x - 7,8x | 7,4x |
| Fair Value | $19,47 - $21,95 | $20,71 |
| Upside | 0,1% - 12,8% | 6,4% |
| Benchmarks | Ticker | Full Ticker |
| AstraZeneca PLC | AZN | LSE:AZN |
| Genomma Lab Internacional, S.A.B. de C.V. | LAB B | BMV:LABB |
| Merck KGaA | 14 | LSE:0O14 |
| Merck & Co., Inc. | 0QAH | LSE:0QAH |
| KYORIN Pharmaceutical Co., Ltd. | 4569 | TSE:4569 |
| GSK plc | GLAX.F | OTCPK:GLAX.F |
| - | - | - |
| Select LTM EBIT Multiple | |||||||
| Benchmark Companies | |||||||
| AZN | LAB B | 14 | 0QAH | 4569 | GLAX.F | ||
| LSE:AZN | BMV:LABB | LSE:0O14 | LSE:0QAH | TSE:4569 | OTCPK:GLAX.F | ||
| Historical EBIT Growth | |||||||
| 5Y CAGR | 33.3% | 10.9% | 9.9% | 18.5% | 10.9% | -5.5% | |
| 3Y CAGR | 64.6% | 8.6% | -1.7% | 21.5% | 35.9% | 3.2% | |
| Latest Twelve Months | 33.1% | 22.6% | 15.7% | 39.3% | 108.9% | -28.4% | |
| Historical EBIT Profit Margin | |||||||
| 5 Year Average Margin | 18.4% | 19.8% | 19.7% | 31.5% | 5.4% | 24.6% | |
| Prior Fiscal Year | 21.1% | 19.5% | 17.6% | 26.6% | 5.0% | 27.7% | |
| Latest Fiscal Year | 23.9% | 21.0% | 19.3% | 38.8% | 9.6% | 19.7% | |
| Latest Twelve Months | 24.8% | 21.3% | 19.5% | 38.2% | 9.6% | 19.8% | |
| Current Trading Multiples | |||||||
| EV / LTM Revenue | 4.30x | 1.38x | 2.61x | 3.39x | 0.57x | 2.19x | |
| EV / LTM EBITDA | 12.9x | 5.9x | 9.5x | 7.5x | 4.3x | 8.0x | |
| EV / LTM EBIT | 17.4x | 6.5x | 13.4x | 8.9x | 5.9x | 11.1x | |
| Low | Mid | High | |||||
| Benchmark EV / LTM EBIT | 5.9x | 8.9x | 17.4x | ||||
| Historical EV / LTM EBIT | 9.4x | 9.6x | 16.2x | ||||
| Selected EV / LTM EBIT | 11.0x | 11.6x | 12.1x | ||||
| (x) LTM EBIT | 6,251 | 6,251 | 6,251 | ||||
| (=) Implied Enterprise Value | 68,649 | 72,262 | 75,875 | ||||
| (-) Non-shareholder Claims * | (12,412) | (12,412) | (12,412) | ||||
| (=) Equity Value | 56,237 | 59,850 | 63,463 | ||||
| (/) Shares Outstanding | 4,059.4 | 4,059.4 | 4,059.4 | ||||
| Implied Value Range | 13.85 | 14.74 | 15.63 | ||||
| FX Rate: GBP/USD | 0.7 | 0.7 | 0.7 | Market Price | |||
| Implied Value Range (Trading Cur) | 18.51 | 19.70 | 20.89 | 19.46 | |||
| Upside / (Downside) | -4.9% | 1.2% | 7.4% | ||||
| Equity Waterfall | |||||||
| Benchmark Companies | |||||||
| (in millions) | AZN | LAB B | 14 | 0QAH | 4569 | GLAX.F | |
| Enterprise Value | 239,450 | 25,832 | 56,104 | 215,731 | 74,314 | 71,523 | |
| (+) Cash & Short Term Investments | 5,395 | 2,157 | 1,620 | 9,228 | 16,514 | 4,485 | |
| (+) Investments & Other | 1,900 | 0 | 1,048 | 1,793 | 21,831 | 1,032 | |
| (-) Debt | (31,717) | (6,957) | (8,698) | (34,844) | (28,439) | (18,432) | |
| (-) Other Liabilities | (92) | 0 | (75) | (65) | 0 | 503 | |
| (-) Preferred Stock | 0 | 0 | 0 | 0 | 0 | 0 | |
| (-) Other | 0 | 0 | 0 | 0 | 0 | 0 | |
| Value of Common Equity | 214,936 | 21,031 | 49,999 | 191,843 | 84,220 | 59,111 | |
| (/) Shares Outstanding | 1,550.6 | 977.8 | 434.8 | 2,511.0 | 57.4 | 4,059.4 | |
| Implied Stock Price | 138.61 | 21.51 | 115.00 | 76.40 | 1,466.00 | 14.56 | |
| FX Conversion Rate to Trading Currency | 1.34 | 1.00 | 1.00 | 1.00 | 1.00 | 0.75 | |
| Implied Stock Price (Trading Cur) | 103.72 | 21.51 | 115.00 | 76.40 | 1,466.00 | 19.46 | |
| Trading Currency | GBP | MXN | EUR | USD | JPY | USD | |
| FX Rate to Reporting Currency | 1.34 | 1.00 | 1.00 | 1.00 | 1.00 | 0.75 | |